What Should We Expect After a Complete Cytoreduction at the Time of Interval or Primary Debulking Surgery in Advanced Ovarian Cancer?
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
What Should We Expect After a Complete Cytoreduction at the Time of Interval or Primary Debulking Surgery in Advanced Ovarian Cancer?
Authors
Keywords
Overall Survival, Ovarian Cancer, Median Overall Survival, Advanced Ovarian Cancer, Peritoneal Cancer Index
Journal
ANNALS OF SURGICAL ONCOLOGY
Volume 23, Issue 5, Pages 1666-1673
Publisher
Springer Nature
Online
2015-12-30
DOI
10.1245/s10434-015-5051-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial
- (2015) Sean Kehoe et al. LANCET
- Prognostic role and predictors of complete pathologic response to neoadjuvant chemotherapy in primary unresectable ovarian cancer
- (2014) Marco Petrillo et al. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY
- The impacts of neoadjuvant chemotherapy and of debulking surgery on survival from advanced ovarian cancer
- (2014) Barry Rosen et al. GYNECOLOGIC ONCOLOGY
- TP53 K351N mutation-associated platinum resistance after neoadjuvant chemotherapy in patients with advanced ovarian cancer
- (2014) Guo-nan Zhang et al. GYNECOLOGIC ONCOLOGY
- Recurrence Patterns of Advanced Ovarian, Fallopian Tube, and Peritoneal Cancers After Complete Cytoreduction During Interval Debulking Surgery
- (2014) Tomoka Usami et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Progress in Survival Outcomes in Patients with Advanced Ovarian Cancer Treated by Neo-Adjuvant Platinum/Taxane-Based Chemotherapy and Late Interval Debulking Surgery
- (2013) Eberhard Stoeckle et al. ANNALS OF SURGICAL ONCOLOGY
- Timing and Pattern of Recurrence in Ovarian Cancer Patients with High Tumor Dissemination Treated with Primary Debulking Surgery Versus Neoadjuvant Chemotherapy
- (2013) M. Petrillo et al. ANNALS OF SURGICAL ONCOLOGY
- Class III β-tubulin overexpression within the tumor microenvironment is a prognostic biomarker for poor overall survival in ovarian cancer patients treated with neoadjuvant carboplatin/paclitaxel
- (2013) Dana M. Roque et al. CLINICAL & EXPERIMENTAL METASTASIS
- An international assessment of ovarian cancer incidence and mortality
- (2013) Kimberly A. Lowe et al. GYNECOLOGIC ONCOLOGY
- Optimal (≤1cm) but visible residual disease: Is extensive debulking warranted?
- (2013) J.N. Barlin et al. GYNECOLOGIC ONCOLOGY
- Introduction of staging laparoscopy in the management of advanced epithelial ovarian, tubal and peritoneal cancer: Impact on prognosis in a single institution experience
- (2013) A. Fagotti et al. GYNECOLOGIC ONCOLOGY
- Histopathology predicts clinical outcome in advanced epithelial ovarian cancer patients treated with neoadjuvant chemotherapy and debulking surgery
- (2013) Miho Muraji et al. GYNECOLOGIC ONCOLOGY
- Survival impact of complete cytoreduction to no gross residual disease for advanced-stage ovarian cancer: A meta-analysis
- (2013) Suk-Joon Chang et al. GYNECOLOGIC ONCOLOGY
- Platinum resistance after neoadjuvant chemotherapy compared to primary surgery in patients with advanced epithelial ovarian carcinoma
- (2013) J. Alejandro Rauh-Hain et al. GYNECOLOGIC ONCOLOGY
- Neoadjuvant chemotherapy with six cycles of carboplatin and paclitaxel in advanced ovarian cancer patients unsuitable for primary surgery: Safety and effectiveness
- (2013) Vanessa da Costa Miranda et al. GYNECOLOGIC ONCOLOGY
- Does neoadjuvant chemotherapy impair long-term survival for ovarian cancer patients? A nationwide Danish study
- (2013) Carsten Lindberg Fagö-Olsen et al. GYNECOLOGIC ONCOLOGY
- Interval Debulking Surgery in Patients with Federation of Gynecology and Obstetrics (FIGO) Stage IIIC and IV Ovarian Cancer
- (2013) Mignon-Denise Keyver-Paik et al. ONKOLOGIE
- Impact of Complete Cytoreduction Leaving No Gross Residual Disease Associated with Radical Cytoreductive Surgical Procedures on Survival in Advanced Ovarian Cancer
- (2012) Suk-Joon Chang et al. ANNALS OF SURGICAL ONCOLOGY
- Neoadjuvant chemotherapy, interval debulking surgery or primary surgery in ovarian carcinoma FIGO stage IV?
- (2012) Claes G. Tropé et al. EUROPEAN JOURNAL OF CANCER
- Role of Neoadjuvant Chemotherapy in the Management of Stage IIIC–IV Ovarian Cancer
- (2012) Sarah Cornelis et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Maximal Cytoreduction in Patients With FIGO Stage IIIC to Stage IV Ovarian, Fallopian, and Peritoneal Cancer in Day-to-Day Practice
- (2012) Mathieu Luyckx et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Primary Debulking Surgery Versus Neoadjuvant Chemotherapy in Stage IV Ovarian Cancer
- (2011) J. Alejandro Rauh-Hain et al. ANNALS OF SURGICAL ONCOLOGY
- The impact of disease distribution on survival in patients with stage III epithelial ovarian cancer cytoreduced to microscopic residual: A gynecologic oncology group study
- (2011) Chad A. Hamilton et al. GYNECOLOGIC ONCOLOGY
- An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT)
- (2011) Dennis S. Chi et al. GYNECOLOGIC ONCOLOGY
- Neoadjuvant Chemotherapy Cannot Be Regarded as Adequate Routine Therapy Strategy of Advanced Ovarian Cancer
- (2011) Andreas du Bois et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Evolution of platinum resistance in high-grade serous ovarian cancer
- (2011) Susanna L Cooke et al. LANCET ONCOLOGY
- Influence of Residual Tumor on Outcome in Ovarian Cancer Patients With FIGO Stage IV Disease
- (2010) Pauline Wimberger et al. ANNALS OF SURGICAL ONCOLOGY
- Role of maximal primary cytoreductive surgery in patients with advanced epithelial ovarian and tubal cancer: Surgical and oncological outcomes. Single institution experience
- (2010) Michele Peiretti et al. GYNECOLOGIC ONCOLOGY
- Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer
- (2010) Ignace Vergote et al. NEW ENGLAND JOURNAL OF MEDICINE
- Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: A combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials
- (2009) Andreas du Bois et al. CANCER
- Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm
- (2009) Dennis S. Chi et al. GYNECOLOGIC ONCOLOGY
- The Optimal Debulking after Neoadjuvant Chemotherapy in Ovarian Cancer: Proposal Based on Interval Look During Upfront Surgery Setting Treatment
- (2009) T. Onda et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Evaluation of New Platinum-Based Treatment Regimens in Advanced-Stage Ovarian Cancer: A Phase III Trial of the Gynecologic Cancer InterGroup
- (2009) Michael A. Bookman et al. JOURNAL OF CLINICAL ONCOLOGY
- Aggressive surgical strategies in advanced ovarian cancer: A monocentric study of 203 stage IIIC and IV patients
- (2008) P.-E. Colombo et al. EJSO
- The effect of maximal surgical cytoreduction on sensitivity to platinum-taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer
- (2007) Eric L. Eisenhauer et al. GYNECOLOGIC ONCOLOGY
- The impact of bulky upper abdominal disease cephalad to the greater omentum on surgical outcome for stage IIIC epithelial ovarian, fallopian tube, and primary peritoneal cancer
- (2007) Oliver Zivanovic et al. GYNECOLOGIC ONCOLOGY
- Tumor Residual After Surgical Cytoreduction in Prediction of Clinical Outcome in Stage IV Epithelial Ovarian Cancer: A Gynecologic Oncology Group Study
- (2007) William E. Winter et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation